Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Erectile dysfunction, a new symptom for the cardiologist].

F Philippe1, P Bondil

  • 1Département de pathologie cardiaque, institut mutualiste Montsouris, 42, boulevard Jourdan, 75014 Paris, France. francois.philippe@imm.fr

Annales De Cardiologie Et D'Angeiologie
|August 23, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Achievement of Target Gain Larger than Unity in an Inertial Fusion Experiment.

Physical review letters·2024
Same author

Lawson Criterion for Ignition Exceeded in an Inertial Fusion Experiment.

Physical review letters·2022
Same author

[Splenogonadal fusion: A case report].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2021
Same author

Observations of anomalous x-ray emission at early stages of hot-spot formation in deuterium-tritium cryogenic implosions.

Physical review. E·2021
Same author

[Costs of healthcare resource consumption after a myocardial infarction in France: An estimate from a medicoadministrative database (GSB)].

Annales de cardiologie et d'angeiologie·2017
Same author

Two crystal x-ray spectrometers for OMEGA experiments.

The Review of scientific instruments·2016

Erectile dysfunction is now a cardiovascular concern. Type 5 phosphodiesterase inhibitors (5-PDEI) are safe for heart patients, and erectile dysfunction may signal silent heart disease.

Area of Science:

  • Cardiology
  • Urology
  • Pharmacology

Context:

  • Erectile dysfunction (ED) was historically managed by urologists and sexologists with limited treatment options.
  • The advent of sildenafil in 1999 revealed the role of endothelial dysfunction and type 5 phosphodiesterase inhibitors (5-PDEI) in treating ED.
  • Increased medicalization and media attention have shifted ED management towards cardiology.

Purpose:

  • To explore the evolving role of cardiologists in managing erectile dysfunction.
  • To address cardiovascular safety concerns associated with 5-PDEI.
  • To highlight ED as a potential early marker for cardiovascular disease.

Summary:

  • Cardiovascular safety of 5-PDEI has been established in registries, showing good tolerability even in patients with coronary heart disease when nitrates are avoided.

Related Experiment Videos

  • ED is frequently associated with cardiovascular risk factors, making it a relevant concern for cardiologists.
  • Erectile dysfunction is recognized as a potential indicator of silent myocardial ischemia and significant coronary artery disease, prompting further cardiac evaluation.

    • Impact:

    • Cardiologists should consider ED as a "herald of silence" for myocardial ischemia.
    • ED necessitates a more proactive approach to evaluating and managing cardiovascular risk factors in patients.
    • The Princeton consensus offers guidelines for cardiologists to assess cardiovascular risk in patients presenting with ED.